换一批
换一批Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
作者：
关键词
ACEi, angiotensin-converting enzyme inhibitorADA, American Diabetes AssociationAR, androgen receptorARB, angiotensin II receptor blockerARTS, minerAlocorticoid Receptor Antagonist Tolerability StudyBP, blood pressureCKD, chronic kidney diseaseCV, cardiovascularCVD, cardiovascular diseaseDM, diabetes mellitusDN, diabetic nephropathyESKD, end-stage kidney diseaseFIDELIO-DKD, Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney DiseaseFIGARO-DKD, Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney DiseaseGLP-1 RA, glucagon-like peptide 1 receptor agonistsGR, glucocorticoid receptorHF, heart failureHFrEF, heart failure with reduced ejection fractionKDIGO, Kidney Disease Improving Global OutcomesMR, mineralocorticoid receptorMRA, mineralocorticoid receptor antagonistPR, progesterone receptorRAAS, renin–angiotensin–aldosterone systemRAS, renin–angiotensin systemSGLT-2i, sodium-glucose cotransporter 2 inhibitorT2DM, type 2 diabetes mellitusUACR, urinary albumin-creatine ratioeGFR, estimated glomerular filtration rate
DOI
10.1016/j.mayocpiqo.2022.09.002
PMID
36277502
发布时间
2024-09-06
- 浏览7
Mayo Clinic proceedings. Innovations, quality & outcomes
2022年6卷6期
536-551页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
